Introduction
In born errors of metabolism (IEMs) have a strong predilection for the nervous system. From the estimated 300 "new" disorders described in the 5 years between the 5th (2011) and the recent 6th (2016) edition of the classic clinical textbook Inborn Metabolic Diseases: Diagnosis and Treatment, 1 85% display predominantly neurological manifestations. Neurodevelopment is constantly interrupted in the pediatric neurologic presentations of IEMs. The precise neurobiological stage of development that is affected and the associated clinical manifestations are both terms related to the main groups of pathophysiological categories found in these diseases, as well as to the specific mechanisms of brain damage linked to every particular IEM. Additionally, neurodevelopment and neurodegeneration can behave as opposites throughout disease evolution, but they may also run in parallel.
C l i n i c a l r e s e a r c h

Neurodevelopment and metabolism: some basic concepts
Neurodevelopment begins in the early prenatal stage with a complex process that starts with the proliferation of distinct cell types, followed by differentiation into various fates, migration to their proper locations, and integration into functional circuitries. 4 These steps continue to evolve in the postnatal years due to functions such as plasticity, myelination, and the maturation of brain cell connectivity. Therefore, neurodevelopment encompasses an important period of time in the life of a human being that goes from early fetal life until the beginning of adulthood. If everything goes well, the highly specialized human brain will be capable of developing a series of intriguing abilities, such as complex language, cognition, emotion, and a repertoire of precise and coordinated movements. 5 Neurodevelopment disorders can arise as cognitive, neuropsychiatric, or motor problems 6 and in general traits include, intellectual disability, learning difficulties, attention deficit hyperactivity disorder, autism, and cerebral palsy. 7 The abnormal functioning of molecules involved in IEM can disrupt neurodevelopment at different stages producing a wide repertoire of clinical manifestations that oscillate from severe brain malformations to mild neurological signs such as learning difficulties (Tables I and II) .
Defects in the proliferation of progenitors in the ventricular zone 8 lead to microcephaly and are predominantly those of centrosomes and centrioles, involving structural proteins and microtubules, which in turn affect proliferation and cell migration. However, most of these defects are not considered as metabolic disorders. IEM that disturb proliferation are related to amino acid, fatty acid synthesis, and complex lipid metabolism defects ( Table I) .
Defects in neuronal migration, which occur from the 2nd to the 6th month of gestation, 9 give rise to lissencephaly and other types of cortical gyration defects (pachygyria, polymicrogyria). IEM leading to deficiencies of both small molecules (amino acids, fatty acids) ( Table I ) and complex molecules (phosphatidyl inositides, cholesterol, peroxisomal metabolism, O-glycosylation, and trafficking defects) ( Table II) are related to migration defects, as well as some energy defects (ie, fumarase deficiency). Flaws found in other neurobiological processes of brain development include:
• Synapse formation and maturation 10 which occurs essentially in the last trimester as well as in the first 2 years of life. Synaptic dysfunction presents itself through a series of symptoms such as intellectual disability (ID), epilepsy, neuropsychiatric signs, and movement disorders in any combination.
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• Myelination, that begins in the second half of gestation and goes on to adolescence. 12 Defects in myelination are related to connectivity defects (ID, neuropsychiatric disorders, epilepsy) and motor problems (spasticity, peripheral neuropathy).
• Cytoskeletal rearrangements are crucial for every aspect of neurodevelopment (regulation of cell division, migration, dendritic and axonal growth, transport of cargo along those fibers). Cytoskeletal dysfunction is related to migrational defects (malformations), axonal conduction (spasticity, peripheral neuropathy), and dendritic dysfunction (symptomatic spectrum of synaptopathies). 13 Synapse formation and maturation, myelination and cytoskeletal functions are very likely to be affected by most IEM since metabolism is an important regulator of these functions. The role of metabolism in the biology of neurodevelopment has scarcely been explored. Some recent works point to relevant functions of glucose 14 purines, pyrimidines, 15 lipids, and autophagy 16 in the molecular mechanisms which regulate brain growth and neuronal connectivity. From the "metabolic side," very few IEMs have been explored from the neurodevelopmental perspective. However, neurodevelopment is constantly disturbed in the pediatric presentations of inherited metabolic diseases.
Neurodevelopment versus neurodegeneration in IEM: opposites or a continuum
Due to the fact that brain function is still one of the most unknown mysteries of biology, concepts and approaches that could have been well-established in the past, can be seen as a matter of controversy nowadays. This is the case for neurodevelopment and neurodegeneration. Initially considered as opposite ends of the spectrum, an accumulating body of evidence shows significant similarities between cellular processes involved in both of them. 2, 3, 17 For that matter, an important question includes the extent to which rare neurodevelopmental diseases have progressive pathology across the Main neurological presentations, pathophysiological categories, and neurodevelopmental to neurodegenerative features. Main clinical presentations are presented depending on the severity degree, from antenatal malformations to isolated symptoms. It is not rare that the same disease could have different types of presentation. Severe global encephalopathies include genetic defects that lead to early disruption of fundamental biological processes that are required for a proper brain development and affect motor, cognitive and behavioural aspects. Synaptopathies correspond to diseases impairing synaptic communication and often have epilepsy, intellectual disability, behavioural abnormalities (including autism) and movement disorders in any combination. Synaptic diseases produce connectivity impairments (abnormal brain circuitries' organization). Complex motor presentations correspond to diseases leading to abnormal motor symptoms; these are related to brain structures and circuits that regulate voluntary and passive movements, strength and muscle tone. In pediatrics' IEMs it is not rare to detect combinations of different motor signs (dyskinetic movements, pyramidal signs, hypotonia, ataxia…). Some additional explanations: COG6 plays a major role in Golgi trafficking and positioning of glycosylation enzymes. HCFC1: gene responsible for X-linked cobalamin deficiency. PHARC: Acronym for a neuropathy syndrome due to a phospholipid remodeling defect that mimics Refsum disease. PIGA is one of the 7 proteins require for the 1st step of the GPI synthesis. C l i n i c a l r e s e a r c h lifespan into adulthood, and how these potentially neurodegenerative mechanisms may inform more common diseases. For trisomy 21 and Rett syndrome, the existence of both neurodevelopmental and neurodegenerative pathology is well-known. 18 Interestingly, IEMs provide many examples of these apparently paradoxical clinical outcomes. In this sense we could consider the following situations: 1. IEMs that disrupt biological programs at any stage of neurodevelopment but then remain stable over time. In fact they tend to have a constant improvement as long as they follow a proper treatment (in those treatable disorders). This is the case of treatable disorders of small molecules such as urea cycle defects, homocystinurias, and other aminoacidopathies. A major constraint in this group of diseases is the lack of knowledge about long-term outcomes. There are few reports on neurological and mental health status at old age, even in those IEMs that have been studied for a long time. Recent articles point towards a significant percentage of neuropsychiatric problems in adolescents and adults in diseases such as urea cycle defects and organic acidurias. 19, 20 2. IEMs that mimic neurodevelopmental disorders such as learning difficulties, ID, neuropsychiatric signs (ADHD, autism) and cerebral palsy because they present with similar symptoms and onset age, and remain apparently stable. However, this stability evolves towards clinical impairment and then to a degenerative course. 17, 21 This is the case of some lysosomal disorders such as Sanfilippo disease, that may start with symptoms mimicking ADHD, and BPAN (an autopaghy disorder) that often presents initially as autism and Rett-like phenotype. 22 The time span between stability and progressive symptoms is variable and represents a major trait that characterizes every disease. Additionally, the interaction between genetic and environmental factors probably has an important role and modulates the mixed neurodevelopmental and neurodegenerative coexistence. 3. IEMs that present as pure neurodegenerative diseases because of the rapid and dramatic progressive outcome or due to adult presentations. These are just descriptions of clinical scenarios without the confirmation of appropriate pathological studies. This is the case for patients that after a number of years of being asymptomatic, present with psychiatric, motor, or cognitive decline. Lysosomal disorders are amongst the most frequent in this group. 23, 24 Neurodevelopment is linked to reduced neuronal arborization, abnormal dendritic morphology, and failures in synapse development. 25 Neurodegeneration appears as gliosis, neuronal loss, and other specific markers such as apoptosis and protein aggregation. It is unknown if even those neurodegenerative diseases starting in adulthood may have pathology changes linked to neurodevelopmental dysfunction that are clinically silent. 26 The lack of necropsy studies, animal models, and high-resolution brain image techniques prevents delineation of the hypothetical continuum of neurobiological disturbances. Figure 1 is a tentative overview to connect neurological presentations with pathophysiological IEM categories and neurodevelopmental to neurodegenerative features.
Classification of IEM with implications in neurodevelopment
Metabolism involves thousands of proteins: mostly enzymes, receptors, and transporters of which the deficits cause IEM. Deficits can affect small or complex molecules. Regardless of their size, metabolites involved in 304 fatty acid elongase 4; FAt: fatty acid transporter; FAs: fatty acid synthetase; FADH: fatty alcohol deshydrogenase; FAHN: fatty acid hydroxylase associated neurodegeneration; FARS 2: mt phenylalanine-tRNA synthetases; GABA:g aminobutyric acid; Glu: glutamine synthetase; GLUT1: glucose transporter; GluR: glutamate receptor; GlyR: glycine receptor; GM: ganglioside; HCFC1: host cell factor C1; HHH: hyperammonemia, hyperornithinemia, homocitrullinemia syndrome; MARS2: mt methionyl-tRNA synthetases. MTHFR: methyltetrahydrofolate reductase; MD: movement disorders; ML: mucolipidosis; MLD: metachromatic leucodystrophy; MPS III: mucopolysaccharidosis type III (sanfilippo disease); NBIA: neurodegeneration with brain iron accumulation; NCL: neuronal ceroid lipofuschinosis; NPSY: neuropsychiatric symptoms; OA: organic aciduriasO-gly: O-glycosylation; PC: pyruvate carboxylase; PDH: pyruvate deshydrogenase; perox: peroxysome biogenesis defects; PHARC: polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataracts; PIGA: phosphatidylinositol glucosaminyltransferase; PI3K/AKT: phosphatidyl inositides kinase; PLA2G6: phospholipase A2; PNPLA6: phospholipase B; PNPO: pyridox(am)ine 5'-phosphate oxidase; Ser: serine synthesis defects; SERAC1: serine active site containing protein 1; SNAP29: synaptosomal associated protein 29 KD; SNX14: sorting nexin 14 SV: synaptic vesicle; tRNAs: tRNA synthetases; TPP: thiamine pyrophosphate; VARS2 mt valyl-tRNA synthetases; VPS15 is also known as PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 4: PIK3R4; WDR45: WD repeat containing protein 45. IEMs can behave in the brain as signaling molecules, structural components, and fuels, and many metabolites have more than one role. According to Morava, the "classification of a disorder as an IMD requires only that impairment of specific enzymes or biochemical pathways is intrinsic to the pathomechanism." 27 Using this extended definition the more recent tentative nosology of IEM encompasses more than 1100 IEMs currently identified and provisionally classified into 130 groups. 28 A "simplified" classification of IEMs mixes practical diagnostic approach and pathophysiological considerations according to 3 large categories based on the size of molecules ("small and simple" or "large and complex") and their implication in energy metabolism. 29 Only some very specific references focused on the more recent and significant defects will be cited while the more classic and well-known IEM will be referred to in the recent clinical textbook Inborn Metabolic Diseases: Diagnosis and Treatment. 
Small molecule defects
Almost all these IEM have plasma and urine metabolic marker(s) (small diffusible water-soluble molecules) that can be easily and rapidly measured in emergency, in one run (such as amino acids, organic acids, acylcarnitine chromatography), or by using specific methods (such as metals or galactose metabolites).
There are two subcategories in small-molecule disorders defined by whether the phenotype primarily results from an accumulation or a deficiency ( Table I) .
Small molecule diseases linked to an accumulation of compounds
These cause acute or progressive "intoxication" disorders. Signs and symptoms result primarily in the abnormal accumulation of the compound(s) proximal to the block and can potentially reverse as soon as it is removed. They do not interfere with embryo and fetal neurodevelopment and they present after a symptom-free interval (days to years: late onset) with clinical signs of "intoxication" (acute, intermittent, chronic, and even progressive: neurodegeneration) provoked by fasting, catabolism, fever, intercurrent illness, and food intake. Most of these disorders are treatable and require the removal of the "toxin" by special diets, scavengers, and cofactors.
This group encompasses IEMs of amino acid catabolism (like phenylketonuria, maple syrup urine disease, or homocystinurias), urea cycle defects, organic acidurias (such as methylmalonic, or glutaric aciduria type 1), galactosemias, metals accumulation (such as Wilson disease, neuroferritinopathies and brain iron accumulation syndromes, or cirrhosis dystonia syndrome with hypermanganesemia). 30 Some purines/pyrimidines and metabolite repair defects (D/L-2-OH-glutaric, NAXE mutations) are also included in this group. Hyperglycinemias behave more so as neurotransmitters disorders than as an intoxication (see following section). Vitamins in metabolism (transport and intracellular processing) interfere with many different metabolic pathways where they act as enzymatic cofactor, chaperone, or signalling molecules. Therefore IEM of vitamins may turn out to be an intoxication treatable disorder or a complex severe congenital encephalopathy.
In the brain, molecules that accumulate can behave as neurotransmitters in the case of amino acids or stimulate biological pathways related to impaired autophagy and nerve growth factors. Secondary disturbances of essential amino acid (AA) transport are commonly observed in case of an elevation of one specific neutral AA using the L-type AA carrier like phenylalanine or leucine in phenylketonuria (PKU) and maple syrup urine disease respectively. This observation has been used to treat PKU. 31 Synaptic plasticity and excitability are almost constantly impaired and executive functions are especially vulnerable. Therefore, and in spite of a proper metabolic control, most of these patients display learning, behavioural and emotional difficulties. 
Small molecule diseases linked to a deficiency
Symptoms result primarily from the defective synthesis of compounds that are distal from the block or from the defective transportation of an essential molecule through intestinal epithelium, blood-brain barrier, and cytoplasmic or organelle membranes. Clinical signs are, at least in theory, treatable by providing the missing compound. Most of these defects cause a neurodevelopmental disruption, have a congenital presentation (antenatal), and may present as birth defects ( Table I) . They share many characteristics with disorders in the complex molecules group (Table II) .
This group encompasses all carrier defects of essential molecules that must be transported through cellular C l i n i c a l r e s e a r c h membranes, and inborn errors of non-essential amino acids, and fatty acid synthesis. The most paradigmatic IEM linked to brain carrier defects are SLC7A5 deficiency resulting in defective transport of the branched chain amino acids (BCAA), 33 and MFSD2A deficiency resulting in defective transport of essential fatty acids such as docosahexanoic acid (DHA). 34 Interestingly the rare disorder branched chain dehydrogenase kinase (BCDHK) deficiency, which overactivates irreversible BCAA oxidation, causing very low levels of BCAA as in SLC7A5 mutations, presents a similarly devastating neurological syndrome with neurodevelopmental disruption. 35 Non-essential amino acid synthesis defects may present also in antenatal life in the form of neurodevelopmental disruption. All severe forms of serine synthesis defects cause Neu Laxova syndrome. 36 Glutamine synthetase 37 and asparagine synthetase 38 deficiencies display an almost complete agyria and clinically present with a severe congenital epileptic encephalopathy. Less severe forms of these disorders present with ID and epilepsy. This variation of clinical manifestations may be common in many other disorders. Severe defects affect early developmental stages and behave as brain malformations whereas mild forms may present as "synaptopathies."
Fatty acids either derived from dietary sources or synthesized de novo can be converted into longerchain fatty acid either saturated, mono-, or polyunsaturated to be further incorporated in complex lipids. 39 Elongase 4 deficiency 40 may present early in infancy with neurodevelopmental arrest, intellectual disability, spasticity, seizures, and ichthyosis similar to the Sjogren Larsson syndrome ( Table I) . Fatty acid synthesis/elongation defects share many similarities with peroxysomal very-long-chain fatty (VLCFA) acid catabolic disorders and complex lipids synthesis and remodeling deficiencies.
In addition to amino acid and fatty acid metabolism defects, the small molecules group also encompasses the IEM of neurotransmitters and those causing metal deficiency 30 such as the manganese transporter deficiency syndrome (SLC39A8), 41, 42 the copper transporter ATP 7B deficiency causing Menkes disease and the copper regulator AP1S1 deficiency causing the MEDNIK syndrome. 43 Inborn errors of neurotransmitters encompass the monoamine transport and synthesis, the g-amino butyric acid (GABA) and GABA receptor deficiency, the glycine cleavage and transport defects and the glutamate defects. The diagnosis of monoamine disorders is based on CSF monoamine and neopterin analysis of carefully collected samples. In general, glycine and GABA defects are detected by means of amino acid quantification in plasma and urine (and also in the CSF for glycine-related disorders). 44 In summary, most small-molecule defect disorders produce major neurodevelopmental disruptions, thereby leading to severe global encephalopathies where almost all neurological functions are chronically altered. In early-onset presentations, patients display severe psychomotor delays affecting both motor and cognitive milestones. Microcephaly and hypomyelination are very common as are epilepsy and movement disorders, which may demonstrate distinct features specific to each particular disease. These defects mimic early "non-metabolic" genetic encephalopathies that affect crucial neurodevelopmental functions such as neuronal precursor proliferation, migration, pruning, and dendrite development. This is because these small molecules contribute to antenatal brain "construction" in terms of signaling, cytoskeleton guidance, synapse formation later on in experience-dependent synapse remodelling.
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Complex molecule defects
This expanding group encompasses diseases that disturb the metabolism of complex molecules that are neither water soluble or diffusible. The main chemical categories of such complex molecules encompass glycogen, sphingolipids, phospholipids, cholesterol and bile acids, glycosaminoglycans, oligosaccharides, glycolipids, and nucleic acids. Similar to the small molecules, there are also two subcategories in complex molecule disorders, defined by whether the phenotype primarily results from an accumulation or a deficiency.
Complex molecule diseases linked to an accumulation
Catabolism defects lead to storage of a visible accumulated compound like classical lysosome defects. They are the most typical and historical group (such as the sphingolipidoses or mucopolysaccharidoses) in which signs and symptoms primarily result from the abnormal 
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Complex molecule diseases linked to a deficiency
Phospholipids (PL) and sphingolipids (SPL) synthesis/ remodeling defects compose a new rapidly expanding group of disorders without storage signs. 39, 46 Many SPL/ PL remodeling disorders present as late-onset neurodegenerative diseases (hereditary spastic paraplegia: HSP,HSP+). Phosphatidylinositides (P-ins) are PL synthesized from cytidyl diphosphate diacylglycerol and inositol, and are highly regulated by a set of kinases and phosphatases. The P-ins 3 kinases (PIK3) are a family of signaling enzymes that regulate a wide range of processes including cell growth, proliferation, migration, metabolism, and brain development. Several disorders in this enzymatic system lead to megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndromes. 47 In general, there is no metabolic marker and diagnosis is mostly based on molecular genetic techniques (eg, targeted next generation sequencing or whole exome sequencing).
Most cholesterol synthesis disorders may present with various multiple congenital and morphogenic anomalies including brain, internal organ, skeletal, or skin anomalies, and/or a marked delay in psychomotor development. Accumulation of substrate and consequent toxicity, with or without cholesterol deficiency, also explains the diversity of phenotypes observed. Alternatively, the anomalies might be attributable, at least in part, to deficient hedgehog signaling as has been suggested in CK syndrome and Smith Lemli Opitz syndrome. 48 Diagnosis is based on plasma oxysterols analysis by gas chromatography/ mass spectrometry. Several bile acid synthesis defects present as late-onset neurodegenerative disorders after a symptom-free period following a transient episode of neonatal cholestatic jaundice. 29 Glycosaminoglycan and oligosaccharide synthesis disorders do not present with preponderant neurological symptoms (therefore not presented here).
Peroxisomal disorders
Deficits may affect a specific matrix enzyme or a peroxin involved in the peroxysome membrane biogenesis. Many peroxysome biogenesis disorders interfere with neurodevelopment in the fetal life with a broad spectrum of phenotypes ranging from the severe Zellweger syndrome with cortical migration defect to mild ID. Peroxisomes play an indispensable role in the oxidation of VLCFA, pristanic, bile acids, and eisosanoids, the deficit of which causes severe neurological consequences. Out of all of them the D-bifunctional protein is the only one that may interfere with antenatal development and can mimic classic Zellweger syndrome. In both, diagnosis is based upon VLCFA, phytanic acid, and plasmalogen determinations in blood, RBC, and fibroblasts. 49 Peroxisomal disorders are examples of early neurodevelopmental disruptions leading later on to neurodegeneration.
Congenital disorders of glycosylation
Congenital disorders of glycosylation (CDG) should be considered in any unexplained clinical condition, particularly in multiorgan disease with neurological involvement but also in nonspecific developmental disability. 50 Many CDG interfere with neurodevelopment in the fetal life, particularly the protein O-glycosylation and lipid O glycosylation and glycosyl phosphatidyl inositol disorders. Cerebellar and olivopontocerebellar atrophy are a frequent finding in many protein N-glycosylation defects. 51 Screening methods are limited to serum transferrin isoelectrofocusing (for N-glycosylation disorders with sialic acid deficiency) and serum apolipoprotein C-III isoelectrofocusing (for core 1 mucin-type O-glycosylation disorders). Exome/genome sequencing is increasingly used in the diagnostic workup of patients with CDG-X. 50 
Intracellular trafficking and processing disorders
Many defects affecting systems involved in intracellular trafficking, vesiculation, processing, and quality control of complex molecules, such as protein folding and autophagy 52 have been recently discovered using next-generation sequencing. These diseases produce a wide repertoire of neurological symptoms including neurodevelopmental defects at various stages, progressive, and neurodegenerative disorders. 32 Significant examples that involve either a category of molecules (like SNARE proteins), 53 ,54 a metabolic process (like autophagy) 55 or the synaptic vesicle cycle 11 are presented in Table II . In general there is no metabolic marker and diagnosis relies on molecular investigations.
t-RNA synthetases
Aminoacyl-tRNA synthetases (aaRSs) catalyze the specific attachment of each of the 20 amino acids to a cognate tRNA. With the exception of GARS and Peroxisomal ß-oxidation: PZO plays an indispensable role in the oxidation of VLCFA, pristanic, bile acids, and eisosanoids the deficit of which causes severe neurological deficits C l i n i c a l r e s e a r c h KARS, mitochondrial and cytoplasmic aaRSs are encoded by distinct nuclear genes. 56, 57 Aminoacyl-tRNA synthetases deficiencies present with a broad clinical spectrum. Interestingly, the neurological phenotypes range from later onset peripheral neuropathy (the socalled Charcot Marie Tooth type II) to severe, multisystem developmental syndromes. Mitochondrial aaRSs deficiencies may mimic an OXPHOS disorder with hyperlactatemia. 58 Diagnosis relies on molecular technics. Only those with preponderant neurological signs are presented in Table II .
Nucleic acid disorders
Purine and pyrimidine synthesis and metabolism play major roles in controlling embryonic and fetal development and organogenesis. Any defect altering the tight regulation of purinergic transmission and purine and pyrimidine metabolism during pre-and post-natal brain development may translate into functional deficits, which could be at the basis of severe pathologies characterized by mental retardation or other disturbances. 15 This can occur either at the level of the re-
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Cytoplasmic t-RNA
The recessive neurological phenotypes associated with cytoplasmic ARSs include hypomyelination, microcephaly, seizures, sensorineural hearing loss, and developmental delay. Some multisystem, cytoplasmic ARS-linked disorders also include liver dysfunction and lung disease. Dominant ARS-mediated disorders have, to date, a limited phenotypic range. Mutations in five ARS loci have been implicated in dominant Charcot-Marie-Tooth (CMT) disease and related neuropathic phenotypes: glycyl-(GARS), tyrosyl-(YARS), alanyl-(AARS), histidyl-(HARS), and tryptophanyl-tRNA synthetase (WARS). ARS-mediated CMT disease is predominantly caused by a defect in peripheral nerve axons (CMT Type 2).
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VII Purines and Pyrimidines
Diagnosis is based on P, U biomarkers (GCMS and HPLC), enzyme assays. Many enzymatic defects affecting the de novo synthesis, catabolic and salvage metabolic pathways of purines and pyrimidine involve brain development. 59 A few disorders are potentially treatable like CAD deficiency that presents with an early severe epileptic encephalopathy responsive to uridine.
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ABH12: α/β hydrolase domain-containing protein 12APBD that releases arachidonic acid; ADHD; attention deficient hyperactivity disorder; APBD: adult polyglucosan body disease; ASMD: acid-sphingomyelinase deficiency; AA: amino acids; AP-5: adaptor proteins (AP 1-5) are ubiquitously expressed protein complexes that facilitate vesicle-mediated intracellular sorting and trafficking of selected transmembrane cargo proteins; AP-5 is part of a stable complex with two other proteins, spatacsin (SPG11) and spastizin (SPG15); ARCA: autosomal recessive cerebellar ataxia; ASD: autism spectrum disorder; BPAN: β-propeller proteinassociated neurodegeneration; B4GALT1-CDG: GM2 synthetase; CAD: enzymatic complex responsible for the first three steps of the de novo pyrimidine synthesis; CER I/II: ceramide synthetase I/II; COG: conserved oligomeric Golgi complex (plays a major role in Golgi trafficking and positioning of glycosylation enzymes; CP: cerebral palsy; DDHD1/DDHD2: encode an A1 phospholipase; EPG-5 protein is critically involved in the late stages of the autophagy cascade such as autophagosome-lysosome fusion or proteolysis within autolysosomes; FAHN: fatty acid hydroxylase associated neurodegeneration; GBA2: Non lysosomal glucosylcerebrosidase; GCMS: gas chromatography mass spectrometry; GD2: disialoganglioside; GM1/2 monosialoganglioside; GOSR2: Golgi SNAP that indirectly regulates exocytosis; receptor GPI: Glycosylphosphatidylinositol; HSP: Hereditary spastic paraplegia; ID: intellectual disability; FA: Fatty acids; HM: hypomyelination; MKD-MA: mevalonate kinase-mevalonic aciduria; MMA Methylmalonic acid; NABP: N-ethylmaleimide-sensitive factor attachment protein beta implicated in synaptic vesicle docking; NALD: Neonatal adrenoleukodystrophy; NBIA: Neurodegeneration with brain iron accumulation; NDEG: neurodegeneration; NR: not reported; NDEV: neurodevelopmental; NPSY: neuropsychiatric; NSDHL: NAD(P) dependent steroid dehydrogenase-like; PEX: peroxin integral proteins of PZO membrane; PIGA: phosphatidylinositol glucosaminyltransferase (one of the 7 proteins require for the 1st step of the GPI synthesis); PMM2: phosphomannomutase 2; PNPLA6: phospholipase B; PLA2G6: phospholipase A2; PPRT: proline rich transmembrane protein 2 that regulates exocytosis; PZO: Peroxysome; Rabenosyn-5: multidomain protein implicated in receptor-mediated endocytosis and recycling; RCDP: rhizomelic chondrodysplasia punctata; RP: retinitis pigmentosa; SENDA: static encephalopathy of childhood with neurodegeneration in adulthood; SERAC1: protein with a lipase domain involved in the remodeling of phosphatidylglycerol, bis monoacyl glycerol phosphate and cardiolipin; SNAP 25: synaptosomal associated protein that regulates the neurotransmitter release; SNAP29: encodes for a SNARE protein involved in vesicle fusion; SRD5A3-CDG: steroid 5-alpha reductase; STXBP1:syntaxin binding protein 1 that regulates exocytosis; STX1B: syntaxin 1B that regulates exocytosis; VLCFA: very long chain fatty acids; VPS15 mutations perturb endosomal-lysosomal trafficking and autophagy; WDR45 interacts with autophagy proteins Atg2 and Atg9 to regulate autophagosome formation and elongation; WM: white matter; ZW: Zellwegger (*) This variation of clinical manifestations may be common in many other disorders. Severe defects affect early developmental stages and behave as brain malformations whereas mild forms may present as "synaptopathies." cruitment and/or signaling of specific nucleotide or nucleoside receptors or through genetic alterations in key steps of the purine salvage pathway. The pathophysiology of neurological signs remains badly known in many deficits such as in Lesch Nyhan syndrome. 59 Some deficits are potentially treatable, like the uridine-responsive epileptic encephalopathy linked to CAD deficit, a protein complex involved in the first three steps of pyrimidine synthesis. 60 Diagnosis relies on plasma/urines purines and pyrimidines profiles, specific enzymes assays and molecular studies.
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Disorders involving primarily energy metabolism
These consist of IEM with symptoms due, at least in part, to a deficiency in energy production or utilization within the brain, and other tissues. Inadequate ATP synthesis is an obvious issue for cells with constant or intermittently high energy demands such as neurons, which need to propagate action potentials. Astrocytes must recycle neurotransmitters released by neurons, a process that likely accounts for a large proportion of the brain's energy budget. Mitochondria are also key components of metabolic signaling pathways and a range of metabolites play key roles in influencing cellular function.
Membrane carriers of small energetic molecules
These molecules (glucose, fatty acids, ketone bodies, monocarboxylic acids) display many tissue specific isozymes such as the glucose cerebral transporter (GLUT1) and the monocarboxlic acid transporter (MCT). Glucose is the obligatory fuel for adult brain, but lactate produced from glucose by astrocytes within brain during activation has been proposed to serve as neuronal fuel. This simple and seductive hypothesis has been recently severely questioned. 61 Clinically, and disregarding whatever the source of ATP may be, only essential fatty acid carrier deficiency presents with antenatal manifestations while GLUT1 62 and MCT1 63 deficiencies present only with relatively mild postnatal and late onset manifestations.
Mitochondrial defects
These are the most severe and difficult to treat. The 289 genes categorized as causing mitochondrial disease can be divided into those that have a primary role specific to OXPHOS biogenesis, and those whose impact on OXPHOS is indirect or involve other cellular functions. 64 Based on their function, the encoded proteins can be roughly grouped into 1) OXPHOS subunits, assembly factors and electron carriers 2) mtDNA maintenance 3) mtDNA expression 4) enzyme cofactors 5) mitochondrial homeostasis and quality control 6) general metabolism.
Brain manifestations of mitochondrial diseases are very frequent and cover a large variety of early postnatal to late-onset adult clinical features including seizures, encephalopathy, ataxia, spasticity, dystonia, movement disorders, parkinsonism, stroke-like episodes, developmental delay and/or regression, and cognitive decline. 65 Aerobic glucose oxidation defects presenting with congenital lactic acidemias may display antenatal manifestations such as cerebral dysgenesis, corpus callosum atrophy, cerebral and cerebellar heterotopy, microcephaly, (pyruvate dehydrogenase system, pyruvate transporter, pyruvate carboxylase, fumarase and other Krebs cycle defects). 66 Most of them have a progressive course. Some patients with severe forms of electron transfer (ETF) flavo protein and ETF ubiquinone oxidoreductase, 67 and carnitine palmitoyl transferase II 68 may have congenital anomalies with polycystic kidneys and neuronal migration defects that can be detected prenatally by fetal MRI , and facial dysmorphism.
Cytoplasmic energy defects
These are generally less severe. They include systemic glycolysis disorders, inborn errors of pentose phosphate pathways (untreatable), and creatine metabolism disorders (partially treatable).
Conclusions
Most, if not all, IEMs that involve the nervous system result in major neurodevelopmental disruptions. This is true not only for the "classic" historical group of "intoxication" disorders, with markers allowing a metabolic screening, but also for the vast new group of complex molecules disorders without easy-to-reach metabolic marker so far. This new, extended definition of IEM in-cludes new categories and mechanisms, and as a general trend goes beyond a single biochemical pathway and/ or organelle, and appears as a connection of multiple crossroads in a systems biology approach. 32 Clinical features are very diverse and may present as a neurodevelopmental disorder (antenatal or late onset), as well as an intermittent, a fixed chronic, or a progressive neurodegenerative disorder. This is observed also within the same disorder in which a continuum spectrum of severity is frequently seen. However, little is still known about the biological mechanisms that potentially connect both neurodevelopment disorders and neurodegeneration. Therefore this linkage should be viewed as a hypothesis rather than a conclusion. An important issue to be addressed is the lack of natural history descriptions in most of these rare disorders. A deeper and detailed knowledge about how these disorders evolve over time, which symptoms will have a trend to improve, and which others will appear or worsen, is badly needed in order to understand the impact of these IEM through the lifespan. Moreover, these studies will be useful to monitor the effect of upcoming new treatments.
Recent molecular techniques have considerably contributed to the description of many new diseases and many new unexpected phenotypes. However metabolomics and lipidomics stand out among -omics due to the fact that they study the end products of cellular processes and therefore are more likely to be representative of clinical phenotypes than genetic variants or changes in gene expression. 69 A greater understanding of phenotypic variability will be critical to personalize, or at least weigh, the initiation of long-term, sometimes burdensome, therapies in diseases detected by expanded newborn screening but that can manifest only in adulthood and with milder phenotypes. 70 
